NDA 208692 · Exelixis INC
Cabometyx
Cabozantinib S-Malate · Oral
Breakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Oct 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 25, 2016
Approved uses
8
Original approval plus efficacy supplements
Registered trials
45
3 Phase 3, 6 recruiting
FAERS reports
45,867
20,559 serious, 5,123 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 19, 2025.
CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab ( 1.1 ) patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.2 ) adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible ( 1.3 ) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET). ( 1.4 ) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET). ( 1.4 ) 1.1 Renal Cell Carcinoma CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced RCC. 1.2 Hepatocellular Carcinoma CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. 1.3 Differentiated Thyroid Cancer CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible. 1.4 Neuroendocrine Tumors CABOMETYX is indicated for the treatment of adult and pediatric...
Mechanism: In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 10, 2025 Supplement 18 · Efficacy OrphanLetterLabel
- Mar 26, 2025 Supplement 17 · Efficacy OrphanLabelLetter
- Jul 14, 2022 Supplement 14 · Efficacy LetterLabel
- Sep 17, 2021 Supplement 12 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Jan 22, 2021 Supplement 10 · Efficacy · priority review LabelLetter
- Jan 14, 2019 Supplement 3 · Efficacy OrphanLabelLetter
- Dec 19, 2017 Supplement 2 · Efficacy · priority review LabelLetter
- Apr 25, 2016 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyOrphanLabelReviewOther
3 products under this application
- CABOMETYX · CABOZANTINIB S-MALATE EQ 60MG BASE · TABLET, ORAL · Prescription · TE AB
- CABOMETYX · CABOZANTINIB S-MALATE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
- CABOMETYX · CABOZANTINIB S-MALATE EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Cabozantinib S-Malate" as an intervention, any sponsor and status, largest first.
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaPivotal-lookingSuspended
National Cancer Institute (NCI)NIH
NCT05691478 · 1,122 participants (planned) · Start Mar 3, 2023 · Primary completion Mar 20, 2030
Drug: Cabozantinib S-malate; Cisplatin and 2 more · For: High Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma and 1 more
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 202 sites in all
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05092958 · 654 participants (planned) · Start Jun 3, 2022 · Primary completion Jul 15, 2029
Drug: Avelumab; Cabozantinib S-malate · For: Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma and 15 more
Sites: Phoenix, Arizona; Auburn, California; Berkeley, California · 275 sites in all
National Cancer Institute (NCI)NIH
NCT03866382 · 314 participants (planned) · Start May 13, 2019 · Primary completion Feb 28, 2027
Drug: Cabozantinib S-malate; Ipilimumab and 1 more · For: Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 582 sites in all
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03375320 · 298 participants · Start Oct 26, 2018 · Primary completion Aug 23, 2023
Drug: Cabozantinib S-malate · For: Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm and 25 more
Sites: Anchorage, Alaska; Kingman, Arizona; Phoenix, Arizona · 432 sites in all
- Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05411081 · 200 participants (planned) · Start Mar 24, 2023 · Primary completion Jul 1, 2027
Drug: Atezolizumab; Cabozantinib S-malate · For: Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
Sites: Gilbert, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 198 sites in all
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01835158 · 157 participants · Start Jul 8, 2013 · Primary completion Apr 18, 2016
Drug: Cabozantinib S-malate; Sunitinib Malate · For: Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7 and 1 more
Sites: Mobile, Alabama; Anchorage, Alaska; Burbank, California · 488 sites in all
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02761057 · 152 participants · Start Jul 25, 2016 · Primary completion Oct 19, 2023
Drug: Cabozantinib S-malate; Crizotinib and 2 more · For: Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7 and 4 more
Sites: Anchorage, Alaska; Kingman, Arizona; Fort Smith, Arkansas · 595 sites in all
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02496208 · 152 participants (planned) · Start Jul 22, 2015 · Primary completion Jul 30, 2027
Drug: Cabozantinib S-malate; Ipilimumab and 1 more · For: Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma and 27 more
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea8,923
- fatigue7,330
- off label use6,092
- nausea4,724
- decreased appetite4,414
- malignant neoplasm progression3,284
- blood pressure increased3,107
- palmar-plantar erythrodysaesthesia syndrome3,042
- weight decreased2,872
- death2,797
- stomatitis2,731
- constipation2,284
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 16 |
| 2014 | 107 |
| 2015 | 87 |
| 2016 | 159 |
| 2017 | 1,452 |
| 2018 | 3,369 |
| 2019 | 3,853 |
| 2020 | 2,940 |
| 2021 | 4,546 |
| 2022 | 5,885 |
| 2023 | 6,053 |
| 2024 | 6,461 |
| 2025 | 6,037 |
| 2026 | 4,898 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cabometyx (Cabozantinib S-Malate)
2024 spending
$1.22B
Beneficiaries
9,182
50,232 claims
Per beneficiary
$132,512
$826.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $380,754,686 |
| 2021 | $662,754,254 |
| 2022 | $919,262,057 |
| 2023 | $1,109,315,042 |
| 2024 | $1,216,725,023 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
Duke ES, Barone AK, Chatterjee S, et al. · Clin Cancer Res 2022 · Randomized Controlled Trial
- Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.
Lee D, Muthukumar M, Lovell A, et al. · Health Technol Assess 2026 · Network Meta-Analysis, Systematic Review
- U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.
Singh H, Brave M, Beaver JA, et al. · Clin Cancer Res 2017 · Randomized Controlled Trial
- Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.
Nguyen L, Chapel S, Tran BD, et al. · J Pharmacokinet Pharmacodyn 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ, Wakefield V, Cain P, et al. · Health Technol Assess 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
Lacy S, Nielsen J, Yang B, et al. · Cancer Chemother Pharmacol 2018 · Clinical Trial, Phase III, Comparative Study
Sponsor: Exelixis INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.